期刊
NEUROBIOLOGY OF AGING
卷 36, 期 2, 页码 1140-1150出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2014.09.022
关键词
Amyotrophic lateral sclerosis; AMPK; Bioenergetics; Pre-conditioning; Spinal cord; Motoneuron degeneration; SOD1
资金
- Science Foundation Ireland [08/IN.1/B1949]
- Irish Health Research Boards [HRA_POR/2011/108]
- Health Research Board (HRB) [HRA-POR-2011-108] Funding Source: Health Research Board (HRB)
Adenosine 50-monophosphate-activated protein kinase (AMPK) is a master regulator of energy balance. As energy imbalance is documented as a key pathologic feature of amyotrophic lateral sclerosis (ALS), we investigated AMPK as a pharmacologic target in SOD1(G93A) mice. We noted a strong activation of AMPK in lumbar spinal cords of SOD1(G93A) mice. Pharmacologic activation of AMPK has shown protective effects in neuronal preconditioning models. We tested the hypothesis that preconditioning with a small molecule activator of AMPK, latrepirdine, exerts beneficial effects on disease progression. SOD1(G93A) mice (n = 24 animals per group; sex and litter matched) were treated with latrepirdine (1 mu g/kg, intraperitoneal) or vehicle from postnatal day 70 to 120. Treatment with latrepirdine increased AMPK activity in primary mouse motor neuron cultures and in SOD1(G93A) lumbar spinal cords. Mice preconditioned with latrepirdine showed a delayed symptom onset and a significant increase in life span (p < 0.01). Our study suggests that preconditioning with latrepirdine may represent a possible therapeutic strategy for individuals harboring ALS-associated gene mutations who are at risk for developing ALS. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据